PROCEPT BioRobotics Corporation - Common Stock (PRCT)
21.42
-1.47 (-6.42%)
NASDAQ· Last Trade: Aug 12th, 11:52 AM EDT
Detailed Quote
Previous Close
22.89
Open
22.45
Bid
21.40
Ask
21.43
Day's Range
21.41 - 22.68
52 Week Range
16.67 - 42.71
Volume
285,700
Market Cap
-
PE Ratio (TTM)
-12.53
EPS (TTM)
-1.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,898,104
Chart
About PROCEPT BioRobotics Corporation - Common Stock (PRCT)
Procept Biorobotics Corp is a medical technology company focused on advancing minimally invasive surgical solutions, particularly for the treatment of benign prostate hyperplasia. The company develops innovative robotic-assisted platforms that enhance the precision and effectiveness of procedures, empowering urologists to deliver better patient outcomes while reducing recovery times. Procept aims to transform standard surgical practices through its cutting-edge technology, improving the overall experience for both patients and healthcare providers. Read More
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the “Class Period”).
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) of the September 22, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.
NEW YORK CITY and NEW ORLEANS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NasdaqGM: PRCT), if they purchased the Company’s shares between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Robbins Geller Rudman & Dowd LLP announces that purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, both dates inclusive (the “Class Period”), have until September 22, 2026 to seek appointment as lead plaintiff of the Procept class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691 (N.D. Cal.), the Procept class action lawsuit charges Procept as well as certain of Procept’s top current and former executive officers with violations of the Securities Exchange Act of 1934.
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Procept (PRCT) To Contact Him Directly To Discuss Their Options
LOS ANGELES, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation (“Procept” or “the Company”) (NASDAQ: PRCT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the “Class Period”).
NEW ORLEANS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation (NasdaqGM: PRCT) (“Procept” or the “Company”), if they purchased the Company’s shares between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the “Class Period”).
LOS ANGELES, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation (“Procept” or “the Company”) (NASDAQ: PRCT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
